Searchable abstracts of presentations at key conferences in endocrinology

ea0092ps2-14-03 | Case Reports 1 | ETA2023

Two cases of radioactive iodine refractory malignant struma ovarii with nras mutation

Yoo Jungmin , Kim ChaeA , Yong Kim Tae , Bae Kim Won , Eun Song Dong , Gu Kim Won

Background: Struma ovarii is a germ cell tumor of the ovary containing ≥ 50% thyroid tissue and malignant struma ovarii (MSO) is a very rare disease containing papillary or follicular thyroid carcinomas (FTC). There is no consensus on optimal management for patients with MSO and no data on radioactive iodine (RAI) responsiveness. Here, we report two cases with RAI refractory MSO with NRAS mutation detected by next-generation sequencing (NGS). Case ...

ea0041ep1095 | Thyroid cancer | ECE2016

Clinical usefulness of dynamic risk stratification in medullary thyroid cancer

Han Ji Min , Kwon Hyemi , Kim Won Gu , Jeon Min Ji , Kim Tae Yong , Kim Won Bae , Shong Young Kee

Purpose: To detect persistent/recurrent disease of medullary thyroid carcinoma (MTC) after initial surgery is important. The Tumor-Node-Metastasis (TNM) staging system is useful for predicting disease-specific mortality, but it is static and does not include postoperative serum calcitonin levels. We focused on the clinical usefulness of dynamic risk stratification (DRS) using the best response to initial therapy in patients with MTC.Methods: A total of 1...

ea0035p387 | Diabetes (epidemiology, pathophysiology) | ECE2014

The HLA-A*33 haplotype enhances the risk of type 1 diabetesin ndividuals with HLA-DR3+ or DR9+ haplotype

Zhang Juanjuan , Gu Weiqiong , Wang Bokai , Gao Jie , Li Li , Cui Bin , Hong Jie , Wang Weiqing , Ning Guang

Background: To investigate the typing for HLA-I in Chinese patients with type 1 diabetes (T1D) as a complement screening for HLA-II.Methods: A total of 212 T1D patients and 200 healthy controls were enrolled. The genetic polymorphisms of HLA-I and II were examined with a high-resolution polymerase chain reaction-sequence-based typing method.Results: The novel haplotype, A*33:03-B*58:01-C*03:02(A33), was a...

ea0029oc3.3 | Diabetes Clinical | ICEECE2012

Diabetic ketoacidosis at diagnosis influences complete remission after treatment of hematopoietic stem cell transplantation in adolescents with type 1 diabetes

Gu W. , Hu J. , Zhu D. , Tang W. , Li L. , Cui W. , Hong J. , Zhang Y. , Wang W. , Ning G.

Objective: To determine if autologous nonmyeloablative hematopoietic stem cell transplantation (AHSCT) was worthwhile to do in type 1 diabetes adolescents with diabetic ketoacidosis at diagnosis.Research Design and Methods: We enrolled 28 type 1 diabetes patients aged 14–30 years in a prospective AHSCT phase II clinical trial. Hematopoietic stem cells were harvested from the peripheral blood following a pretreatment consisting of a combination of cy...

ea0029p829 | Endocrine tumours and neoplasia | ICEECE2012

Enhanced antitumor efficacy of fructose conjugated-gefitinib on lung cancer cell lines in vitro and in vivo

Hui H. , Zhang S. , Ding W. , Li J. , Zhao X. , Zuo M. , Wang X. , Gu W. , Pandol S. , Go V.

Cancer cells have shown an overexpressed fructose transporter GLUT5 and preferential utilization of fructose as compared to glucose, implicating that a fructose-based analogue would be a useful target for diagnosis and treatment of cancer. We have successfully synthesized the fructose conjugated-gefitinib compounds {N-[4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-7-methoxy-quinazolin-6-yl]-4- [N-methyl-N-(1-deoxy-1-fructosyl)]aminobutanamide}, and examined its antitumor effic...

ea0029p1405 | Pituitary Clinical | ICEECE2012

Long-term use of pasireotide in Cushing’s disease: 24-month safety results from a randomized phase III study

Bertherat J , Ludlam W , Pivonello R , Maldonado M , Trovato A , Hughes G , Gu F , Schopohl J , Salgado L

Introduction: Rapid and sustained decreases in UFC and significant improvements in signs and symptoms were seen in a large, randomized, 12-month phase III study of pasireotide in Cushing’s disease. The safety profile of pasireotide was found to be similar to that of other somatostatin analogues, with the exception of hyperglycemia-related AEs (reported in 72.8% of patients). This abstract reports safety data from a 12-month extension to this phase III trial.<p class="...

ea0029p1410 | Pituitary Clinical | ICEECE2012

Long-term pasireotide use leads to improvements in the biochemical parameters of Cushing’s disease: 24-month results from a randomized phase III study

Schopohl J , Bertherat J , Ludlam W , Maldonado M , Trovato A , Hughes G , Gu F , Salgado L , Pivonello R

Introduction: The large, randomized, phase III study of pasireotide in Cushing’s disease found that pasireotide treatment resulted in rapid and sustained decreases in UFC levels and in significant improvements in signs and symptoms over 12 months of treatment. A 12-month extension of this trial has recently completed, and the results are reported here.Methods: Patients with persistent/recurrent or de novo (if not surgical candidates) Cushing&...

ea0016p467 | Neuroendocrinology | ECE2008

Starting dose of 10 mg Octreotide-LAR appears ineffective for biochemical control in the majority of acromegalic patients: interim analysis from the OASIS trial

Petersenn Stephan , Tarasov Alexander , Gu Feng , Kim Sungwoon , Mercado Moises , Rogozinski Amelia , Bouterfa Hakim , David Kristin , Silva Antonio , Greenman Yona

Octreotide LAR (SMS-LAR) is available in 10, 20 and 30 mg dosing. The relation-ship between SMS-LAR starting dose and GH, IGF-I and symptoms was exam-ined. The Observational Acromegaly Study on Impact of Sandostatin LAR (OASIS) collects data on GH, IGF-I, symptoms, safety and tolerability in recently diagnosed acromegalic patients. Data are collected under normal practice conditions over 12 mos. Eight hundred and sixty patients from 138 centers in 23 countries are enrolled; 35...

ea0063p737 | Pituitary and Neuroendocrinology 2 | ECE2019

A multicentre, randomized, open-label, Phase IV study investigating management of pasireotide-associated hyperglycaemia with incretin-based therapy or insulin in patients with acromegaly or Cushing’s disease (CD)

Bolanowski Marek , Gu Feng , Feldt-Rasmussen Ulla , Zhang Shaoling , Yu Yerong , Witek Przemyslaw , Pedroncelli Alberto M , Nauwelaerts Heidi , Jabbour Nadine , Paul Michaela , Samson Susan

Background: Pasireotide has proven efficacy in acromegaly and CD, although pasireotide-associated hyperglycaemia occurs in some patients. This Phase IV, randomized, open-label study investigated optimal management of pasireotide-associated hyperglycaemia uncontrolled by metformin/oral antidiabetic therapy (OAD) [NCT02060383].Methods: Adults with acromegaly or CD were enrolled and treated with long-acting pasireotide 40 mg/28 days or subcutaneous pasireot...

ea0049ep1366 | Thyroid (non-cancer) | ECE2017

Dynamic risk stratification for predicting recurrence in patients with differentiated thyroid cancer treated without radioactive iodine remnant ablation therapy

Park Suyeon , Kim Won Gu , Song Eyun , Oh Hye-Seon , Kim Mijin , Kwon Hyemi , Jeon Min Ji , Kim Tae Yong , Shong Young Kee , Kim Won Bae

Background: Increased incidence of small differentiated thyroid cancer (DTC) has emphasized the need for risk stratification and individualized disease management for these low risk DTCs. The aim was to validate a new dynamic risk stratification (DRS) system for prediction of structural recurrent/persistent disease in patients with DTC treated without radioactive iodine (RAI) remnant ablation therapy.Methods: This historical cohort study included 357 pat...